Immunocore Holdings Ltd (IMCR)

Immunocore Holdings plc announced that its management will participate in four investor conferences in September 2026: Cantor Global Healthcare Conference, Morgan Stanley 24th Annual Global Healthcare Conference, Baird 2026 Global Healthcare Conference, and H.C. Wainwright 28th Annual Global Investment Conference. These participations will include fireside chats and one-on-one meetings. Webcasts of the presentations will be available on the company's website.

JP Morgan has reinstated Immunocore Holdings (IMCR) with an Overweight rating and a price target of $50.00, suggesting the stock is currently undervalued by 17.9% according to GuruFocus's GF Value™. Despite its strong growth potential and overall GF Score™ of 80/100, the biotechnology company faces challenges in profitability, with no insider buy or sell transactions in the last three months indicating stable insider sentiment. Investors are advised to consider the growth narrative against the lack of profitability and cash flow.

JPMorgan has reinitiated coverage on Immunocore Holdings PLC (IMCR) with an Overweight rating and a $50 price target, citing the strong foundation of its lead product KIMMTRAK and upcoming Phase III trial results. Despite current unprofitability, the company's Price-to-Sales ratio is significantly below its historical median, and its GF Value™ suggests it is 19.2% undervalued. The GF Score™ of 80/100 highlights strong growth and valuation, though profitability and financial strength remain areas for improvement.

Immunocore Holdings plc reported a significant improvement in its financial performance, achieving profitability in the first half of 2026 with net income of US$12.16 million, up from a loss the previous year. This positive shift is driven by increased revenue, though the company's investment narrative still heavily relies on the success of its KIMMTRAK drug and ongoing Phase 3 trials for brenetafusp. Despite a recent share price pullback, analysts project substantial revenue and earnings growth by 2028, suggesting a potential undervaluation of the stock.

Immunocore Holdings plc (IMCR) reported a significant improvement in its financial performance, achieving a first-half 2026 net income of US$12.16 million, up from a net loss of US$5.28 million the previous year, with revenues also increasing. This shift to profitability strengthens the investment case, though the company's reliance on KIMMTRAK and the outcomes of its Phase 3 PRISM-MEL-301 trial for brenetafusp remain key factors influencing future growth and risk. Despite a recent share price pullback, analysts' pessimistic revenue forecasts may be re-evaluated given the company's improved earnings and potential for significant upside based on fair value estimates.